Insights
Insights From Our Experts
Articles
Pharmaceutical Contracting from Volume to Value
Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…
Medicaid Drug Classification: Civil Monetary Penalties
On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective…
Gene Therapy for Rare Disorders
With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?
Setting a Patient Engagement Framework and Proving Value
Is your culture patient-centric? It needs to be because today’s patients are motivated information seekers – empowered decision-makers with respect to their treatment. Their voice is key to your success.
Insights from AMCP 2019
EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and…
Develop Patient Support Programs Focused on Patients
Posted by
Private: Tom Doyle on June 19, 20196/19/19
We have to get intimate with patient populations and advocacy groups to build best-in-class patient support programs from the start.
Providing a Patient-Driven Experience
As the “patient-as-consumer” culture enables patients to consider all their varied care options, they increasingly want to be involved not only by participating in clinical trials, but also by accelerating product development and the availability of…
Sell’N Gene Therapies: A Landscape Assessment Of Cell And Gene Therapy Reimbursement
Cell and gene therapies hold great life-saving potential, with the ability to treat disease states with significant morbidity, mortality, or treatment-related complications. Kymriah became the first CAR-T cell therapy to bring transformative efficacy to B-cell acute…
Put Your Patient Services Program to the Test
How well do you really know your patients? Global Genes reports that therapy adherence in the rare disease space can vary from 58 to 65 percent, a troubling statistic for our industry, and most importantly, the…
How Could Policy Changes to Protected Classes Impact Part D Access and Contracting?
(Content Updated 5/17) CMS Protected Class Rule Finalized, Slightly Loosened for Biopharma Following CMS’ 2018 proposed rule allowing for new protected class exceptions and a comment period for stakeholders through the beginning of this year, CMS…